Developing New Compounds for Cannabinoid Receptors
Project 1 - Design and Synthesis of Novel Functionally Selective CB1 and CB2 Cannabinergic Ligands
['FUNDING_P01'] · NORTHEASTERN UNIVERSITY · NIH-11128506
This project creates new compounds that interact with specific cannabinoid receptors in the body, aiming to help with conditions like addiction and certain organ diseases.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHEASTERN UNIVERSITY (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11128506 on ClinicalTrials.gov |
What this research studies
This project focuses on creating new chemical compounds, called ligands, that can specifically interact with the body's CB1 and CB2 cannabinoid receptors. Researchers are using these new compounds to better understand how these receptors work and how they can be controlled. The team is developing these compounds with the hope that they could become new medications for serious conditions like alcohol and opioid addiction. Additionally, these compounds are being explored for their potential to treat fibrotic diseases that affect organs such as the lungs, liver, and kidneys. The ultimate goal is to design compounds that have very specific effects, leading to more effective and targeted treatments.
Who could benefit from this research
Good fit: Patients who might benefit in the future include those living with alcohol or opioid addiction, or individuals with pulmonary, liver, or kidney fibrotic conditions.
Not a fit: Patients not currently experiencing alcohol or opioid addiction or fibrotic conditions would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and more targeted medications for addiction and various fibrotic diseases.
How similar studies have performed: Previous work by this team has successfully developed compounds that are now being tested as potential medications, suggesting a promising foundation for this ongoing research.
Where this research is happening
BOSTON, UNITED STATES
- NORTHEASTERN UNIVERSITY — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAKRIYANNIS, ALEXANDROS — NORTHEASTERN UNIVERSITY
- Study coordinator: MAKRIYANNIS, ALEXANDROS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.